A prevalence of Clostridium difficile-associated diarrhea in hospitalized patients (results of a Russian prospective multicenter study)

Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(4):268-274

​ Dmitrieva N.V., Klyasova G.A., Bakulina N.V., Sukhina M.A., Zhuravel S.V., Belousova E.A., Ivashkin V.T., Goryunov S.V., Prokhorovich E.A., Kameneva T.R., Samsonov A.A., Yakovenko A.V., Kazakov S.V.
Clostridium difficile-associated diarrhea antibiotic-associated diarrhea hospitalized patients enzyme immunoassay glutamate dehydrogenase toxin A toxin B
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(4):268-274

Objective.

The objective of the study was to evaluate the prevalence of Clostridium difficile-associated diarrhea (CDAD) among hospitalized patients with antibiotic-associated diarrhea (AAD) in general and by specific types of medical care and hospital units.

Materials and Methods.

A prospective, cross-sectional, non-interventional, multicenter study. The main inclusion criteria were: patient age of 18 years and over, hospital stay of at least 48 hours, current antibiotic therapy or antibiotic therapy within the previous 30 days, loose stools (Bristol stool types 5-7 and stool frequency ≥3 within ≤24 consecutive hours or exceeding normal for the patient), and signed informed consent form. The stool sample was transported to the local (study site) microbiology laboratory for detection of glutamate dehydrogenase (GDH) and toxins A/B using enzyme immunoassay (EIA) stool test.

Results.

From April 2016 through April 2017, a total of 1,245 patients from 12 large hospitals were enrolled into the study. Data on 81 patients were excluded from the analysis due to the different reasons. Data on 1,164 patients (45.2% males and 54.8% females) with the mean age of 54.9 years (range: 18 to 95 years) were analyzed. Length of hospitalization was 2 to 188 days (median of 8 days). The EIA stool test showed CDAD positive results in 21.7% (253⁄1,164) patients. The patients were from surgery units (546⁄1,164), internal medicine units (510⁄1,164) and intensive care units (108⁄1,164). The prevalence of CDAD among patients from surgery, internal medicine and intensive care units was 26.2%, 17.8% and 17.6%, respectively. Oncology, gastroenterology, septic surgery, oncohaematology and general profiles of hospital units accounted for more than 75% of all patients included; the prevalence of CDAD by those hospital units was 11.3%, 15.0%, 39.2%, 17.6%, and 27.2%, respectively. The proportion of GDH-positive and toxin A/B-negative patients by the rapid stool test result was 16.8% (196⁄1,164). The prevalence of CDAD varied widely between the hospitals (from 0% to 44.3%).

Conclusions.

The prevalence of CDAD among hospitalized patients with AAD in this study was 21.7% (95% confidence interval: 14.8%, 28.7%). The percentage of CDAD varied widely between hospitals and by specific types of medical care and hospital units

Dmitrieva N.V.

N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia

Galina A. Klyasova

National Medical Research Center of Hematology, Moscow, Russia

Bakulina N.V.

North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

Sukhina M.A.

A.N. Ryzhikh State Scientific Center of Coloproctology, Moscow, Russia

Zhuravel S.V.

N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russia

Belousova E.A.

M.F. Vladimirskiy Moscow Regional Research Clinical Institute, Moscow, Russia

Ivashkin V.T.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Goryunov S.V.

City Clinical Hospital #15 named after O.M. Filatov, Moscow, Russia

Prokhorovich E.A.

A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Kameneva T.R.

City Clinical Hospital named after M.P. Konchalovskiy, Moscow, Russia

Samsonov A.A.

A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Yakovenko A.V.

Pirogov Russian National Research Medical University, Moscow, Russia

Stanislav V. Kazakov

JSK «Astellas Pharma», Moscow, Russia

  • 1. McFarland L. Epidemiology, risk factors and treatments for antibioticassociated diarrhea. Dig Dis. 1998;16(5):292-307.
  • 2. Bartlett J. Antibiotic-associated diarrhea. Clin Infect Dis. 1992;15:573-581.
  • 3. Gilbert D. Aspects of the safety profile of oral antimicrobial agents. Infect Dis Clin Pract. 1995;4(Suppl 2):S103-S112.
  • 4. Bartlett J., Chang T., Gurwith M., et al. Antibiotic-associated pseudomembranous colitis due to toxin producing Clostridia. New Engl J Med. 1978;298:531-534.
  • 5. Crobach M., Planche T., Eckert C., et al. European society of clinical microbiology and infectious diseases: Update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22:63-81.
  • 6. Bauer M., Notermans D., van Benthem B., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377:63-73.
  • 7. Lyytikäinen O., Turunen H., Sund R., et al. Hospitalizations and deaths associated with Clostridium difficile infection, Finland, 1996-2004. Emerg Infect Dis. 2009;15:761-765.
  • 8. Soler P., Nogareda F., Cano R. Rates of Clostridium difficile infection in patients discharged from Spanish hospitals, 1997-2005. Infect Control Hosp Epidemiol. 2008;29:887-889.
  • 9. Vonberg R., Schwab F., Gastmeier P. Clostridium difficile in discharged inpatients, Germany. Emerg Infect Dis. 2007;13:179-180.
  • 10. Mulyar N.F., Vereschagina S.A., Fadeeva T.V., Spasov G.P., Kanya O.V. Clostridium difficile associated diarrhea in multidisciplinary hospital. Bjulleten' VSNC SO RAMN. 2012;5(87):72-75. Russian.
  • 11. Zakharova N.V., Fil T.S. Antibiotic-associated diarrhea: stratification of risk factors for development of Clostridium difficile infection in multidisciplinary hospital. Farmateka. 2016;s5:60-64. Russian.
  • 12. Shilnikova I., Petukhova I., Dmitrieva N., Grigoryevskaya Z., Bagirova N. Dynamics of Clostridium difficile-associated diarrhea in the Russian cancer research center. Proceedings of 24th ECCMID, 10-13 May 2014, Barcelona, Spain. Abstr R482.
  • 13. Volchkova E.V., Belousova E.A., Makarchuk P.A., Rusanova E.V., Velikanov E.V. Prevalence of Clostridium difficile infection in hospitalized patients. Al'manah klinicheskoj mediciny. 2014;33:72-76. Russian.
  • 14. Sparks S., Carman R., Sarker M., McClane B. Genotyping of enterotoxigenic Clostridium perfringens fecal isolates associated with antibiotic-associated diarrhea and food poisoning in North America. J Clin Microbiol. 2001;39:883-888.
  • 15. Gravet A., Rondeau M., Harf-Monteil C., et al. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-lukD. J Clin Microbiol. 1999;37:4012-4019.
  • 16. Högenauer C., Langner C., Beubler E., et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med. 2006;355:2418-2426.
  • 17. Bartlett J. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
  • 18. Brito G., Sullivan G., Ciesla W. Jr., et al. Clostridium difficile toxin A alters in vitro-adherent neutrophil morphology and function. J Infect Dis. 2002;185:1297-1306.
  • 19. Hecht G., Koutsouris A., Pothoulakis C., et al. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology. 1992;102:416-423.
  • 20. Akerlund T., Svenungsson B., Lagergren A., Burman L. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol. 2006;44:353-358.
  • 21. Lyras D., O'Connor J., Howarth P., et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009;458:1176-1179.
  • 22. McFarland L., Elmer G., Stamm W., Mulligan M. Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients. Infect Immun. 1991;59:2456-2462.
  • 23. Triadafilopoulos G., Hallstone A. Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology. 1991;101:685-691.
  • 24. Kelly C., LaMont J. Clostridium difficile – more difficult than ever. N Engl J Med. 2008;359:1932-1940.
  • 25. Bagdasarian N., Rao K., Malani P. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015;313:398-408.
  • 26. Rubin M., Bodenstein L., Kent K. Severe Clostridium difficile colitis. Dis Colon Rectum. 1995;38:350-354.
  • 27. Bauer M., Notermans D., van Benthem B., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377:63-73.
  • 28. Bouza E., Dryden M., Mohammed R., et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin Microbiol Infect. 2008;14(Suppl 7):S103-104.
  • 29. Louie T., Miller M., Mullane K., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-431.
  • 30. Bauer M., Notermans D., van Benthem B., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377:63-73.
  • 31. Bartlett J., Gerding D. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S12-18.
  • 32. Lessa F., Gould C., McDonald L. Current Status of Clostridium difficile Infection Epidemiology. Clin Infect Dis. 2012;55(Suppl 2):S65-S70.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared